Table 4 In-hospital morbidity and mortality
|  | Ulinastatin group (n = 142) | Tranexamic acid group (n = 143) | Placebo group (n = 141) | P | |||
|---|---|---|---|---|---|---|---|
| Â | n | % | n | % | n | % | Â |
Mortality in-hospital | 1 | 0.70% | 0 | 0.00% | 1 | 0.71% | 0.602 |
Morbidity in-hospital | |||||||
 Stroke | 0 | 0.00% | 2 | 1.40% | 1 | 0.71% | 0.369 |
 Postoperative MI | 0 | 0.00% | 1 | 0.70% | 2 | 1.42% | 0.361 |
 Renal failure | 0 | 0.00% | 2 | 1.40% | 4 | 2.84% | 0.129 |
 Respiratory failure | 1 | 0.70% | 6 | 4.20% | 9 | 6.38% | 0.040 |
Adverse outcomes in-hospital | |||||||
 Seizure | 0 | 0.00% | 2 | 1.40% | 1 | 0.71% | 0.369 |
 Sudden cardiac arrest | 0 | 0.00% | 1 | 0.70% | 2 | 1.42% | 0.361 |
 Readmission to ICU | 2 | 1.41% | 1 | 0.70% | 3 | 2.13% | 0.594 |
 Reoperation for surgical cause | 2 | 1.41% | 1 | 0.70% | 1 | 0.71% | 0.777 |
 IABP | 1 | 0.70% | 2 | 1.40% | 3 | 2.13% | 0.597 |
 ECMO | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% | – |
 Deep sternal infection | 1 | 0.70% | 0 | 0.00% | 1 | 0.71% | 0.602 |